Pro-Dex (NASDAQ:PDEX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Pro-Dex (NASDAQ:PDEXGet Rating) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Pro-Dex Trading Up 1.2 %

NASDAQ:PDEX opened at $16.60 on Monday. Pro-Dex has a one year low of $12.40 and a one year high of $26.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.39 and a current ratio of 2.73. The firm has a market cap of $59.43 million, a P/E ratio of 15.96 and a beta of 0.94. The firm has a 50-day simple moving average of $18.20 and a 200-day simple moving average of $16.99.

Pro-Dex (NASDAQ:PDEXGet Rating) last posted its quarterly earnings results on Thursday, August 25th. The medical instruments supplier reported $0.38 EPS for the quarter. Pro-Dex had a net margin of 8.97% and a return on equity of 16.75%. The business had revenue of $12.62 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in shares of Pro-Dex by 2.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,126 shares of the medical instruments supplier’s stock worth $1,030,000 after buying an additional 1,535 shares during the last quarter. LSV Asset Management grew its position in Pro-Dex by 13.9% during the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock worth $588,000 after purchasing an additional 4,346 shares during the last quarter. JPMorgan Chase & Co. grew its position in Pro-Dex by 59.2% during the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 7,762 shares during the last quarter. State Street Corp grew its position in Pro-Dex by 5.8% during the 1st quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock worth $197,000 after purchasing an additional 650 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Pro-Dex during the 2nd quarter worth approximately $168,000. Hedge funds and other institutional investors own 13.69% of the company’s stock.

About Pro-Dex

(Get Rating)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Further Reading

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.